The podcast addresses the updated definition, classification, and management of pulmonary hypertension (PH). It highlights the redefinition of pulmonary hypertension as a mean PA pressure greater than 20 mmHg and emphasizes the importance of pulmonary vascular resistance (PVR) in distinguishing between different types of PH. The discussion covers the classification of PH into five groups, stressing the therapeutic implications of accurate categorization, as giving pulmonary vasodilators indiscriminately can be harmful. The podcast further explores the role of echocardiography in screening for PH, focusing on metrics beyond right ventricular systolic pressure. It also touches on the limited treatment options for HF-PEF and the excitement surrounding inhaled Triprostanil for ILD-associated PH, based on preliminary results from the INCREASE study.
Part 1: Definitions, Classification, and Pathophysiology
Part 2: Screening, Metrics, and HF-PEF Research
Part 3: Group 3 PH and Lung Disease Studies
Part 4: Risk Assessment, Technology, and Future Directions
Sign in to continue reading, translating and more.
Open full episode in Podwise
